GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - NEWAMSTERDAM PHARMA CO NV

Explicit Guidance:

• Clinical Milestone Timing: Interim analysis trigger expected by the end of 2024, with Data Safety Monitoring Board (DSMB) readout anticipated in the first quarter of 2025.
• Clinical Milestone Timing: Completion of all remaining cardiovascular studies, including the Rubens trial (T2D/metabolic syndrome population), expected by the end of 2025.
• Clinical Milestone Timing: Data availability for the Rembrandt imaging trial (fixed-nose combination) expected toward the end of 2025.
• Commercial Launch Timing: Commercial availability of the drug (OB) in Europe, specifically Germany, targeted for the end of 2024.
• NDA Filing Strategy: Intent to file for US approval immediately following a positive DSMB decision at the interim analysis; filing timing for final analysis (pre-conclusion vs. concurrent) to be determined via FDA discussion.

Business-Segment Outlook:

• Product Differentiation: The fixed-dose combination (OB + ezetimide) and single-agent OB are positioned to capture demand for aggressive LDL-C lowering, addressing the industry trend toward reaching the lowest possible LDL-C levels.
• Clinical Read-through: Anticipated positive data from PREVAIL (MACE 3 and MACE 4 endpoints) to drive adoption; the company expects the commercial setting to leverage outcome data at the time of launch to enhance peer access.
• Market Trend Alignment: The company notes a renewed focus on aggressive LDL-C therapy across guidelines (following ACC and AHA), creating a favorable environment for branded therapies that lower LDL-C to the lowest possible values.

Market and Competitive Outlook:

• Competitive Landscape (LP(a)): Following the neutral Horizon study (Lp(a) lower), management believes the market will not abandon Lp(a) as a risk factor; patients and physicians continue to seek therapies targeting Lp(a) alongside LDL-C.
• Pricing/Adoption Drivers: The "silver lining" from recent trials is interpreted as a signal to be more aggressive with LDL-C lowering for all patients, including those with elevated Lp(a), necessitating multi-drug or branded therapy solutions.
• Competitive Analogues: Management dismisses the ACCELERATE study (Lilly) as a relevant negative analog due to the use of the direct LDL method (overstating reduction), short duration (2 years), and lack of long-term data compared to REVEAL (4-6 years).

Macro / Industry Outlook:

• Standard of Care Trends: Management argues that recent declines in event rates are driven primarily by baseline LDL-C reduction rather than improvements in standard of care (e.g., PCI procedures are stable, mortality trends remain concerning).
• Regulatory/Study Design Consensus: There is a growing industry consensus on study design (e.g., excluding patients with heart failure where benefit is limited, as seen in Zeus) and the use of beta-quantification for LDL measurement rather than the direct method.
• Therapeutic Trends: The market is shifting toward combination therapies and fixed-dose combinations to achieve aggressive lipid targets.

Strategic Initiatives:

• Portfolio Expansion: Continued progression of the Rubens trial (T2D/metabolic syndrome cohort) to address a population of 20–30 million individuals with elevated LDL but no prior ASCVD event.
• Pipeline Execution: Advancement of the Rembrandt trial to provide imaging data on plaque stabilization/clearance, intended to support commercial messaging with visual evidence akin to oncology tumor shrinkage.
• Product Formulation: Leveraging the launch of both OB and the fixed-dose combination to allow patients to achieve the lowest possible LDL-C targets.

Risks and Headwinds to Outlook:

• Statistical Uncertainty: The company explicitly cautions that interim success is not guaranteed; the study could stop on MACE 3 but not MACE 4, or vice versa. A "continue" decision at interim does not guarantee failure at final analysis, though past studies (Select, Ameren) have shown that early stops often predict later outcomes.
• Blinded Data Interpretation: Management acknowledges risks in interpreting blinded data trends (e.g., event rate slowdowns), noting that drop-in rates and standard of care changes are factors, though they argue these are unlikely to be the primary drivers in Prevail compared to a true drug effect.
• Study Continuation Risk: If the DSMB does not recommend stopping at the interim, the study will run to the end of 2025, delaying potential revenue realization and NDA submission.

Management Tone on the Future:

• Confidence Level: Management expresses strong optimism and confidence, stating they would not have introduced an interim analysis if they did not believe there was a "chance of being successful."
• Data Interpretation: The tone is defensive yet assertive regarding the "slowdown" in event rates; management attributes this decline to a genuine drug effect supported by the Broadway study (a "mini PREVAIL"), rather than standard of care improvements or drop-ins.
• Guidance Caution: The team avoids providing specific statistical thresholds (e.g., exact p-values for MACE 3 vs. MACE 4) to prevent investor misinterpretation of statistical infallibility, emphasizing instead that the study is "well-powered."

Miscellaneous:

• Clinical Trial Specifics: The company highlights the Broadway study as a critical roadmap for PREVAIL, noting nearly identical curves for MACE 3 and MACE 4 at one year, with continued declines observed in the active arm out to two years.
• Industry Learning: Management cites the Zeus and Horizon studies as reinforcing the importance of LDL-C targeting and study design (e.g., avoiding heart failure populations where LDL lowering offers less benefit) in generating successful outcomes.